Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 225,780
  • Shares Outstanding, K 13,250
  • Annual Sales, $ 10 K
  • Annual Income, $ -23,390 K
  • 36-Month Beta 5.19
  • Price/Sales 32,670.71
  • Price/Cash Flow 0.00
  • Price/Book 2.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.73 +3.37%
on 07/27/17
20.00 -18.70%
on 07/17/17
-2.67 (-14.10%)
since 06/27/17
3-Month
15.73 +3.37%
on 07/27/17
22.53 -27.83%
on 05/02/17
-4.73 (-22.53%)
since 04/27/17
52-Week
7.81 +108.19%
on 07/28/16
25.95 -37.34%
on 04/13/17
+8.30 (+104.27%)
since 07/27/16

Most Recent Stories

More News
Biotech Players Lead the Growth Charge in the Legal Cannabis Market

NEW YORK, July 27, 2017 /PRNewswire/ --

AXIM : 8.2050 (-2.91%)
GWPH : 116.83 (+0.86%)
INSY : 11.47 (-4.66%)
LXRP : 0.3699 (+2.75%)
ZYNE : 16.26 (-4.58%)
LXX.CN : 0.455 (+3.41%)
Biotech Players Lead the Growth Charge in the Legal Cannabis Market

The backbone of medical advancement is biotechnology, an industry wrought with the incredible potential of novel drug R&D, but vulnerable to the risk of stringent regulatory approval processes. Within...

AXIM : 8.2050 (-2.91%)
LXRP : 0.3699 (+2.75%)
GWPH : 116.83 (+0.86%)
INSY : 11.47 (-4.66%)
LXX.CN : 0.455 (+3.41%)
ZYNE : 16.26 (-4.58%)
Potential Blockbuster Treatment for Alzheimer's Disease Stands Out Among Medical Cannabis Companies

NEW YORK, July 25, 2017 /PRNewswire/ --

CARA : 13.94 (-4.39%)
IGC : 0.42 (+1.46%)
CBIS : 0.0482 (+1.26%)
VBIO : 1.7900 (-4.53%)
ZYNE : 16.26 (-4.58%)
Billionaires Bet Big On Canada's Newest $22 Billion Market

OilPrice.com News Commentary

APH.TO : 6.43 (-3.02%)
APHQF : 5.1250 (-3.85%)
GWPH : 116.83 (+0.86%)
INSY : 11.47 (-4.66%)
ABBV : 71.73 (-1.18%)
ZYNE : 16.26 (-4.58%)
Zynerba Pharmaceuticals Added to the Russell 3000(R) Index

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today...

ZYNE : 16.26 (-4.58%)
Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program

Phase 1 results will inform potential Phase 2 studies in patients with fibromyalgia and neuropathic pain, planned to start in 2H17

ZYNE : 16.26 (-4.58%)
Legal Cannabis and CBD Markets are Projected to Grow

According to a research report published by Arcview Market Research, the growth of the legal cannabis market is projected to reaccelerate beginning in 2018. Adult use sales would ramp up in Canada, California,...

CBDS : 4.4400 (unch)
AXIM : 8.2050 (-2.91%)
STVFD : 0.6400 (+4.92%)
CIIX : 0.9497 (-0.02%)
VBIO : 1.7900 (-4.53%)
ZYNE : 16.26 (-4.58%)
Zynerba Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today...

ZYNE : 16.26 (-4.58%)
How These Generic Drugs Stocks are Faring? -- MYOS RENS Technology, Akari Therapeutics, Flexion Therapeutics, and Zynerba Pharma

On Thursday, May 18, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Five out of nine sectors ended Thursday's trading session in bullish...

AKTX : 4.50 (-1.53%)
MYOS : 1.68 (-1.18%)
FLXN : 23.83 (-2.89%)
ZYNE : 16.26 (-4.58%)
Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today...

ZYNE : 16.26 (-4.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Support & Resistance

2nd Resistance Point 18.21
1st Resistance Point 17.62
Last Price 16.26
1st Support Level 16.65
2nd Support Level 16.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.